Holen Sie sich die Stockscreener-App
0.000001
9,900%
0.000499
Vaxxinity Inc Aktie (VAXX) Neueste Nachrichten
Vaxxinity, Inc.Class A Common Stock (Nasdaq:VAXX) Stock Quote - The Chronicle-Journal
Vaxxinity Inc Stock: Pioneering Synthetic Vaccines in a Competitive Biotech Landscape for North Amer - AD HOC NEWS
VAXX (Vaxxinity) NASDAQ $0.0001 pre-market 27 Mar 2026: Top loser, clinical risk - Meyka
Vaxxinity Inc stock faces Nasdaq delisting risk amid biotech funding crunch - ad-hoc-news.de
VAXX (Vaxxinity, NASDAQ) at $0.0075 on 19 Mar 2026: Earnings could change momentum - Meyka
Vaxxinity Inc Stock (ISIN: US92239B1035) Faces Uncertainty Amid Biotech Sector Headwinds - AD HOC NEWS
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX) - Defense World
VAXX stock at $0.0001 intraday on 11 Feb 2026: critical risks for NASDAQ holders - Meyka
VAXX Vaxxinity, Inc. drops 99% to $0.0001 on NASDAQ 19 Jan 2026: outlook - Meyka
Analyzing Vaxxinity (NASDAQ:VAXX) and ProMetic Life Sciences (OTCMKTS:PFSCF) - Defense World
Vaxxinity Shares Plummet Amid Extreme Volatility - AD HOC NEWS
Analyzing Vaxxinity (NASDAQ:VAXX) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Tangible book value per share of Vaxxinity, Inc. – OTC:VAXX - TradingView
Hypercholesterolemia Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight - Barchart.com
Space Medicine Market Report 2025 | Innovative Space-Based Regenerative Medicine Aims to Enhance Human Health During Long-Duration Missions - 24matins.uk
Hypercholesterolemia Pipeline 2025: Innovative Clinical Advancements by 25+ Global Leaders – DelveInsight | Featuring companies such as Jiangsu HengRui Medicine Co., Ltd., Merck Sharp & Dohme LLC, Arr - Barchart.com
Dallas District Court Split in High-Stakes Stock Dispute - inForney.com
Migraine Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co - Barchart.com
Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial - The Lancet
Top 6 Healthcare Stock Picks in 2025 - timothysykes.com
PCSK9 Inhibitors Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Pipeline, Therapies, and Companies by DelveInsight - The Globe and Mail
VAXX Stock Price, News & Analysis - Stock Titan
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
How a new kind of vaccine could lead to the eradication of Alzheimer's and dementia - New Scientist
Vaxxinity - The Pharma Letter
A Potential Parkinson’s Treatment Has Promising Results - Time Magazine
Parkinson's Prevention May Include Tetanus Vaccination - Vax-Before-Travel
Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine - Yahoo Finance
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
VAXX Stock Price and Chart — OTC:VAXX - TradingView
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace
Vaxxinity to voluntarily delist from Nasdaq - Investing.com
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewswire
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial - ScienceAlert
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - Pharmaceutical Technology
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024 - Yahoo Finance
Peek inside the Space Coast vaccine lab working to create humanity’s moonshot - WFTV
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - Yahoo Finance
Vaxxinity is brewing up meds for a spacefaring future - Pharma Voice
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology - Citeline News & Insights
Vaxxinity, University of Central Florida launch collaboration to advance medicines for use in space - Fierce Biotech
Vaccines show promise against common chronic diseases - Gavi, the Vaccine Alliance
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference - Stock Titan
Vaxxinity making vaccines to change the world - Labiotech.eu
Vaxxinity, Inc. (VAXX) stock price, news, quote and history - Yahoo Finance Singapore
Researchers return to Alzheimer's vaccines, buoyed by recent drug success - Reuters
Vaxxinity earnings missed by $9.89, revenue fell short of estimates - Investing.com UK
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline - Yahoo Finance
Fast-Tracked Alzheimer’s Vaccine Seems to Work, But Phase 3 Trials Stalled - Being Patient
Molina Rene Paula Net Worth (2025) - GuruFocus
Vaxxinity publishes positive results in Alzheimer’s trial - Longevity.Technology
Innovative Alzheimer's Disease Vaccine Candidate Can Add Value - Vax-Before-Travel
Anti-amyloid drug shows significant immune response in adults with mild Alzheimer’s - Healio
Vaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s Treatment - Yahoo Finance
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director - Yahoo Finance
Vaxxinity Appoints Peter Powchik, M.D., to EVP, Global Scientific Director - citybiz
Parkinson’s Patients Treatment Posts Positive Engagement - Vax-Before-Travel
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients - Yahoo Finance
Michael J. Fox Foundation Funds Parkinson’s Disease Vaccine Candidate - Vax-Before-Travel
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease - Florida Hospital News and Healthcare Report
Vaxxinity celebrates trial success in early Parkinson’s therapy - Clinical Trials Arena
Positive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s Disease - Yahoo Finance
Vaxxinity shares update about potential vaccine UB-312 - Parkinson's News Today
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update - The Chronicle-Journal
Vaxxinity, Inc. (VAXX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
VXX-301, a tau vaccine with optimized properties - bioworld.com
0.49%
1.47%
Kapitalisierung:
|
Volumen (24h):